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Abstract The protein kinase, p38α MAPK, is a key
i n t r a c e l l u l a r t r a n s du c e r o f s t r e s s o r - i n du c ed
neuroinflammatory responses and, as such, is of high
interest as a potential therapeutic target. We recently
reported the synthesis and evaluation of first-in-class
CNS-penetrant and highly specific p38 MAPK inhibitors
that avoid target crossover issues seen in popular small
molecule p38 MAPK inhibitors used in hundreds of
previous reports. The novel p38 MAPK inhibitors, rep-
resented in this study by MW181, are efficacious
in vivo. Pharmacodynamic actions include attenuation
of stressor-induced increases in brain proinflammatory
cytokine levels. We report here more detailed analyses
of MW181 target engagement and specific linkage to
the downstream increase in glia proinflammatory cyto-
kine production. In vivo validation included demonstra-
tion that oral administration of MW181 suppresses
lipopolysaccharide-induced increases in mouse brain
IL-1β, TNFα, IL-6, IL-10, and CXCL1 but not in a
drug-resistant p38α MAPK mutant mouse.
Keywords Mitogen-activated protein kinase . Drug
discovery . Neurodegeneration . Signal transduction .
Cytokine .Microglia
Introduction
Neuroinflammation is a complex process that can be pro-
foundly influenced by the cellular and environmental context,
disease stage, and inciting stimuli. Microglia, as the resident
tissue macrophage, are the archetypal cell in the CNS
neuroinflammatory response. In addition, astrocytes, along
with microglia, represent the resident cells in the nervous
system responsible for neuroinflammation. In response to
injury, infection, or other disturbances, microglia and astro-
cytes activate a patterned response to defend against and
isolate inducing stimuli, which is followed by healing, repair,
and resolution of the neuroinflammation. The reactive re-
sponse of glia is fundamental for CNS homeostasis. However,
the reactive glia response is context specific and highly vari-
able, which can cause beneficial and/or detrimental forms of
neuroinflammation (for a review of reactive gliosis see: Burda
and Sofroniew 2014).
Microglia provide elegant examples of how a reactive glia
response can be beneficial or detrimental. Microglia respond
to a variety of pathological stimuli or other danger signals by
turning on classical immune effector functions, characterized
by the up-regulation of a battery of proinflammatory cytokines
and chemokines, as well as oxidative and nitrosative stress
molecules. These responses help to orchestrate and amplify
beneficial repair responses that are vital to host defense against
danger signals, and allow inactivation and/or phagocytosis of
the pathogen or activating stimuli. However, these same
microglial proinflammatory responses can contribute to
downstream neuronal damage if not contained or attenuated
in appropriate time windows after injury. For a microglia
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response to be beneficial, a careful balance must be main-
tained between protective/reparative and deleterious
microglial activation. Moreover, a protective response in one
context, such as a spinal cord injury, could be detrimental in a
diffuse brain injury, or irrelevant in a degenerative disease.
Overall, if neuroinflammation is inefficient, excessive, or
prolonged, the delicate neuroinflammatory balance will be-
come disrupted resulting in tissue damage, including neuro-
degeneration (for reviews, see Burda and Sofroniew 2014;
Mosher and Wyss-Coray 2014; Ransohoff and Perry 2009).
Differences in diseases and reactive glia responses have
important ramifications for targeting neuroinflammatory re-
sponses as an intervention strategy. Disease-modifying thera-
peutics that inhibit glial activation responses will need to be
selective in their action, act at the appropriate stage of disease
progression, and modulate endpoints or signaling pathways
relevant to the particular neurodegenerative disease indica-
tion. There are numerous potential avenues for target-
specific interventions in molecular events associated with
neuroinflammation. The disease-modifying therapeutic could
act by modulating the ability of the glia to perform a particular
cellular function, such as releasing matrix metalloproteases to
remodel the extracellular matrix. Alternatively, the therapeutic
agent could block the ability of the glia to recognize the
activating stimuli, such as blocking the response to the dam-
age signal ATP by inhibiting purinergic receptor signaling.
Another possibility for a disease-modifying therapeutic would
be not to inhibit the glia response, but instead to block the
ability of that response to elicit an effect on a target cell type
such as the neuron. An example of this approach would be the
use of a biologic, such as IL1ra, to block IL-1β dependent
cytokine signaling.
Extensive evidence has implicated dysregulation and over-
production of proinflammatory cytokines as a contributor to
pathophysiology progression in both chronic and acute neu-
rodegenerative disorders. Taken in its entirety, the evidence is
consistent with the hypothesis that proinflammatory cytokine
up-regulation is a comparatively early event in the progression
of pathophysiology that is causally linked to synaptic dys-
function, behavior deficits and, in the more extreme case,
neuronal death (Van Eldik et al. 2007). This raises the possi-
bility that blocking the production of specific proinflammato-
ry cytokines, and/or blocking the receptor signaling events in
neurons, for example, could be an effective strategy with
potential for disease modification in multiple diseases and
clinical presentations.
One of the most well established intracellular signal trans-
duction cascades involved in the production of proinflamma-
tory cytokines, and cytokine receptor signaling, in both pe-
ripheral and central inflammatory disorders, is the p38MAPK
family, especially the p38α isoform (Arthur and Ley 2013;
Bachstetter and Van Eldik 2010). Using both a pharmacolog-
ical approach with a small molecule p38α inhibitor and a
genetic approach with primary microglia deficient in p38α,
we previously showed (Bachstetter et al. 2011) that this iso-
form is critical for the production of cytokines from activated
microglia. We also demonstrated (Xing et al. 2011, 2013) that
microglial p38α-mediated cytokine overproduction is critical
to inflammation-induced neurotoxicity, whereas the p38β
isoform is not required for proflammatory cytokine produc-
tion or neurotoxicity. Consistent with the above findings, we
showed that myeloid-specific deletion of p38α protects mice
from diffuse brain injury-induced vestibulomotor impairments
and synaptic protein loss (Bachstetter et al. 2013). Overall, an
accumulating body of knowledge demonstrates the impor-
tance of p38α MAPK as a central driver of pathological
microglial activation and detrimental inflammatory responses,
rendering the development of p38α MAPK inhibitors as an
attractive avenue of exploration for new therapies against
CNS diseases and injuries that involve injurious proinflam-
matory cytokine overproduction.
In addition to the role of p38αMAPK in glia, endogenous
neuronal p38α MAPK can also play a role in pathology
progression. For example, neuronal p38α MAPK has been
implicated in the synaptic dysfunction brought about by ex-
cessive proinflammatory cytokine related neuroinflammation
in diverse preclinical models (Tong et al. 2012). Similarly,
axon-autonomous activation of p38αMAPK has been impli-
cated in a gain of toxic function in SOD1 familial amyotrophic
lateral sclerosis due to its role in the regulation of fast
axonal transport (Morfini et al. 2013), which can con-
tribute to the dying-back axonopathy found in such
neurodegenerative disorders.
The prevailing evidence, therefore, raises the potential of a
novel pharmacological paradigm in which enhanced re-
sponses might be possible via targeting the same molecular
target in multiple cell types involved in CNS pathology pro-
gression (i.e. neurons and glia). The novel CNS paradigm
stands in contrast to previous efforts at targeting p38 MAPK
in peripheral tissue disorders where preclinical studies and
clinical trials showed a pharmacodynamics effect of attenuat-
ing blood proinflammatory cytokine levels, but the direct
linkage of the proinflammatory cytokine levels to end organ
damage was less than ideal or engagement of target tissue p38
MAPK activity was not established.
The major challenge for p38 MAPK inhibitor in vivo stud-
ies in CNS disorders was, until recently, the issues found
generally for targeting protein kinases in the CNS (Chico
et al. 2009). The initial major challenge facing any CNS-
targeted drug discovery program is effective blood–brain bar-
rier (BBB) penetration, as only ~2 % of small molecule drugs
exhibit adequate CNS exposure (Pardridge 2005). Another
challenge in development of p38 MAPK inhibitors has been
the ability to achieve selective inhibition of the kinase, as most
of the extant inhibitors target multiple kinases in addition to
p38. This early dependence onmixed kinase inhibitors for p38
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MAPK in hundreds of publications has generated some con-
fusion in the field of signaling research, as well as concern
about the potential of off-target adverse events for drugs
developed from these chemical scaffolds. Especially
perplexing are conclusions based on the mixed p38 MAPK /
casein kinase (CK) inhibitors. For example, re-investigation
has revised conclusions about causative signaling pathways
from being p38 MAPK mediated to being CK1 mediated
(Shanware et al. 2009; Verkaar et al. 2011), and medical
genetics outcomes forecast that decreased CK1 activity can
be a susceptibility factor for migraine (Brennan et al. 2013).
Therefore, it is critical that newly developed p38α MAPK
inhibitors be extensively characterized for kinase selectivity
using large-scale kinome screens, especially for CK crossover,
and their biological mechanism of action be well-validated.
In this regard, we recently reported (Watterson et al. 2013)
the development of a set of efficacious and CNS-penetrant
small molecule p38α inhibitors that large-scale kinome
screens show are selective for the p38 MAPK family, lack
crossover to major GPCR agonist or antagonist classes based
on functional screens, exhibit low toxicity at high doses, and
are efficacious in an Alzheimer’s disease-relevant progressive
brain injury model. The mechanism of pharmacological ac-
tion, or pharmacodynamic effect, includes the suppression of
stressor-induced increases in proinflammatory cytokine pro-
duction. However, there remains a need for further exploration
of biological target engagement and pharmacodynamic action
if caveats from prior art are to be addressed fully.
We report here that the selective inhibitor MW181 engages
its cellular p38α MAPK target with resultant attenuation of
endogenous substrate phosphorylation in activated microglia
cultures. We also report the dose-dependent linkage between
the early decrease in substrate phosphorylation and the down-
stream attenuation of increases in proinflammatory cytokine
levels. The extension to in vivo mechanisms is shown by the
ability of orally administered MW181 to prevent stressor-
induced increases in brain cytokines and chemokines in
wild-type (WT) mice but not in genetically engineered p38α
MAPK inhibitor-resistant mice. These results provide further
validation of the utility of MW181 as a highly selective
chemical biology tool appropriate to study the role of p38α
MAPK in CNS disorders that have neuroinflammation as a
component of the disease mechanism.
Materials and Methods
MW181
MW01-10-181SRM (=MW181) was synthesized as de-
scribed (Watterson et al. 2013). MW181 is a water soluble,
low molecular weight, acidic, small molecule. The HCl salt of
MW181 was used for the cellular and in vivo studies
described here. Stock solutions were made in sterile 0.9 %
sodium chloride free of preservatives.
Cell Culture
MW181 inhibition of lipopolysaccharide (LPS)-induced re-
sponses was tested in the murine microglial BV-2 cell line as
previously described (Watterson et al. 2013). Briefly, cells
were treated with either saline vehicle control or 100 ng/ml
LPS (Salmonella enterica serotype typhimurium (Sigma-Al-
drich: EU/mg of LPS is 600,000)), in the absence or presence
of increasing concentrations of MW181. MW181 was added
to the cultures immediately before the addition of LPS. Cells
were harvested after 1 h of stimulation for western blot anal-
ysis and after 16 h of stimulation for proinflammatory cyto-
kine measurements. Cell permeability and efflux pump sus-
ceptibility (permeability glycoprotein, Pgp) were determined
by Apredica, Inc (Watertown, MA) using the standard Caco-2
two way permeability analysis (Stewart et al. 1995) in the
absence and presence of a known Pgp inhibitor, verapamil,
and monitoring parent drug by HPLC/MS/MS.
Animals
All experiments were conducted in accordance with the Guide
For the Care and Use of Laboratory Animals and approval of
the Institutional Animal Care and Use Committee of the
University of Kentucky. Animal experiments followed the
recent NIH guidelines for rigor in study design and analysis
(Landis et al. 2012; Shineman et al. 2011), including random-
ization of animals, and blinding of treatment groups and tissue
samples. Male and female, 2- to 4-month-old C57Bl/6 mice
(Harlan) were used as wild type (WT) mice. Aged-matched,
male and female, p38α MAPK drug-resistant knock-in
(p38αT106M) mice (p38α KI mice) were generated as previ-
ously described (O’Keefe et al. 2007). In vivo screening of
MW181 compound efficacy was conducted as previously
described (Watterson et al. 2013). Briefly, MW181 (5 or
20 mg/kg) or saline vehicle was administered by oral gavage
(po) in a volume of 200 μL, and mice were given an intraper-
itoneal injection of saline vehicle or LPS (300,000 EU in
100 μL) 1 h later. Mice were euthanized at 6 h after LPS
administration, based on our previous studies showing that
this timepoint is optimal for IL-1β production. Brain was
dissected on ice, snap-frozen in liquid nitrogen, and stored at
−80 °C until time of use.
Western Blotting
Western blotting analysis was performed as previously de-
scribed (Bachstetter et al. 2011), using the following primary
antibodies from Cell Signaling Technology (Beverly, MA):
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pMSK1 (cat. no. 9595 (1:1000)); pMK2 (cat. no. 3041
(1:1000)); GAPDH (cat no. 2118 (1:10000)).
Cytokine/Chemokine Measurements
IL-1β in BV2 lysates was measured using kits from Meso
Scale Discovery (MSD; Gaithersburg, Maryland), and
cytokine/chemokine levels in mouse cortex lysates were mea-
sured using the MSD V-plex assay as previously described
(Watterson et al. 2013).
Statistics
Statistical analysis used GraphPad prism software version 6
(GraphPad Software, San Diego California USA, www.
graphpad.com). For Fig. 1, calculations of IC50 values were
made using a nonlinear regression with a variable Hill slope,
with the data normalized to the positive control to fit the top
and bottom plateaus. For Fig. 2, effect of drug treatment in
LPS-stimulated WT mice was analyzed using a one-way
analysis of variance (ANOVA) followed by Tukey’s multiple
comparison test. Reported P values are adjusted to account for
multiple comparisons. Effect ofMW181 treatment in p38αKI
mice was analyzed using a two-tailed unpaired t-test. No
statistical comparisons were made between mice treated with
and without LPS, and no statistical comparisons were made
betweenWTand p38αKI mice. Therefore, to conserve on the
total number of mice needed, the number of mice used in the
no LPS p38α KI group was limited to n=3. Significance was
defined as a p<0.05. Unless otherwise indicated, values are
expressed as mean ± SEM.
Results
MW181 is Freely Cell Permeable and not a Substrate
for the Pgp Efflux Pump
Interpretation of cellular mechanism of action studies for
small molecules requires adequate cell membrane permeabil-
ity and minimal removal by efflux pumps during the course of
the experiment. A drug predominantly moves by passive
diffusion through cellular membranes (A→B direction) that
comprise tissue barriers. If the drug is a PgP substrate, it is
pumped back out (B→A direction) and eventually excreted
from the body. The Pgp efflux pump status is especially
important for CNS studies, as the pump removes susceptible
small molecules from cells and is a major contributor to blood
brain permeability problems for the vast majority of small
molecule drugs and inhibitors. In addition, Pgp status can
change with disease, drug treatment or innate immune status.
The caco-2 bi-directional transport assay is a calibrated stan-
dard approach used to address permeability, which is a reflec-
tion of the drug’s molecular properties, and to determine if the
drug is a PgP substrate. Briefly, cells are grown as a mono-
layer in a transwell, allowing directional measurement of
Fig. 1 Concentration-dependent ability of MW181 to engage the endog-
enous glia target and suppress proinflammatory cytokine induction. Serial
dilutions of the p38αMAPK inhibitor, MW181, starting at 30 μM, were
added to BV2 cells stimulated with 100 ng/ml of LPS. The levels of
phosphorylated (activated) p38α MAPK substrates pMK2 (a) and
pMSK1 (b) were determined by western blot of cell lysates at 1 h after
LPS addition. At 16 h after LPS addition, levels of the proinflammatory
cytokine IL-1β (c) were measured in cell lysates by MSD ELISA. Data
are presented as percent ofmaximal activity (activity with LPS + vehicle),
and are representative of at least two independent experiments. The log
IC50 values and the IC50 95 % confidence intervals are shown in the gray
boxes within the graphs
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transport. The net flux is determined as a ratio of B→A/A→B.
If the ratio is >2, then more of the drug is pumped back out
than enters by passive diffusion, usually due to the drug being
a PgP substrate. Status is confirmed by incubating in the
presence of a saturating concentration of a specific PgP sub-
strate, verapamil. The competition for the PgP transporter
results in the efflux ratio for the drug changing from >2 to
<2. As summarized in Table 1, MW181 exhibits efflux ratios
<2 in both the absence and presence of a specific PgP inhib-
itor, demonstrating that MW181 has high permeability and is
not a Pgp efflux pump substrate.
MW181 Engages Endogenous Glia p38αMAPK in a
Concentration-Dependent Manner
Mitogen-activated protein kinase-activated protein kinase
2 (MK2) and mitogen- and stress-activated kinase 1
(MSK1) are downstream substrates of p38α MAPK.
To assess target engagement by MW181, we measured
the levels of phosphorylated (p)-MK2 and pMSK1 in
LPS-stimulated glia treated with MW181 at different
concentrations. In our culture conditions without LPS,
a basal activation of pMK2 is observed, which is further
enhanced by LPS stimulation. MW181 was able to
suppress both basal and LPS-induced levels of pMK2
with an IC50 of 1,197 nM (Fig. 1a). MW181 also
inhibited LPS-stimulated pMSK1 levels, with an IC50
of 1,430 nM (Fig. 1b).
MW181 Attenuates Stressor-Induced Proinflammatory
Cytokine Up-Regulation in Microglia
LPS-induced changes in proinflammatory cytokine levels are
evident at later time points compared to the changes in endog-
enous substrate phosphorylation, consistent with prevailing
models of the signal transduction mechanism. We, therefore,
tested the ability of MW181 to suppress LPS-induced up-
regulation of the proinflammatory cytokine IL-1β in the
BV2 microglia cell line at 16 h vs 1 h for substrate phosphor-
ylation. MW181 inhibited IL-1β production in a
concentration-dependent manner, with an IC50 of
599 nM (Fig. 1c).
Fig. 2 MW181 pharmacodynamic effect in WT mice and lack of effect
in drug-resistant p38αT106M MAPK KI mice. Mice were administered
either saline vehicle or MW181 by oral gavage 1 h prior to an intraper-
itoneal LPS (300,000 EU) injection. Cortex was harvested at 6 h after
LPS injection. Levels of inflammatory analytes in the cortical lysates
were measured using MSD v-plex multiplex ELISAs. Data is a summary
of four independent experiments. The experiments were normalized as a
percent of the average of the LPS + veh for the respective experiments.
Level of significance is denoted by *p<0.05, **p<0.01, and ‡p<0.001
Table 1 MW181 has high cell permeability and is not a substrate for Pgp
efflux pump. For apical to basolateral (A→B) permeability, test agent
added to apical side and permeation determined by LC/MS/MSmeasured
on basolateral side; the opposite is done for B→A. Pgp substrate status









bEfflux ratio Recovery Notes
MW181 10 2 36.7 42.5 1.2 88 % High permeability
MW181 + verapamil 10 2 45.2 42.9 0.9 98 % Not a Pgp substrate
a Apparent permeability
b Papp (B→A)/ Papp (A→B)
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Orally Administered MW181 Shows Dose-Dependent
Inhibition of CNS Cytokine Up-Regulation
Replicating the IL-1β result in vivo and extending the data of
Watterson et al. (2013), we found (Fig. 2) a significant effect
of MW181 on cortical levels of IL-1β in wild type mice
(F(2, 47)=4.041; p=0.024). MW181 at 20 mg/kg suppressed
IL-1β levels in LPS-challenged mice (p=0.031), and at
5 mg/kg showed a trend, but when corrected for multiple
comparisons the decrease did not reach significance.
MW181 showed a strong inhibition of TNFα up-regulation
(F(2, 47)=16.39; p<0.0001), with both the 5 mg/kg and
20 mg/kg doses significantly suppressing TNFα levels
(p<0.0001, and p=0.0002; respectively). There was also a
significant effect ofMW181 on IL-6 levels in LPS-treatedWT
mice (F(2, 47)=5,808; p=0.0056); again, 20 mg/kg of MW181
inhibited IL-6 levels (p=0.0071), but the inhibition by
MW181 at 5 mg/kg did not quite reach significance
(p=0.055). At this time window, MW181 also decreased the
anti-inflammatory cytokine IL-10 (F(2, 47)=5.436; p=0.0075)
at both compound concentrations (5 mg/kg, p=0.0334;
20 mg/kg, p=0.0152). However, under the conditions of this
study it cannot be stated if this is a direct effect of MW181 or
feedback loop responses to blockage of proinflammatory cy-
tokine increases. The cortical levels of CXCL1, a chemokine
involved in neutrophil and oligodendrocyte precursor cell
recruitment (Ransohoff 2009), were also reduced by
MW181 treatment (F(2, 47)=5.834; p=0.0055). Both the
5 mg/kg and 20 mg/kg doses of MW181 significantly
suppressed CXCL1 levels compared to the LPS-
stimulated WT mice treated with vehicle (p=0.0122,
and p=0.025; respectively).
Lack of MW181 Pharmacodynamic Effect in the p38αT106M
MAPK Drug-Resistant KI Mice
To further assess in vivo target specificity of MW181 and
better link kinase target engagement by the inhibitor to in vivo
pharmacodynamic endpoints, we took advantage of the
p38αT106M KI mice (O’Keefe et al. 2007). These KI mice
have the endogenous p38α MAPK gene disrupted, but pro-
duce a functional protein kinase resistant to inhibitors that
bind in an active site hydrophobic pocket. The molecular
mechanism of drug resistance is the targeted replacement of
the gatekeeper Thr at residue 106 with a larger side chain Met
amino acid that renders the hydrophobic pocket less accessible
to inhibitors with bulky substituents that occupy this pocket.
We previously showed through the combined use of high-
resolution co-crystallography and comparative structure-
activity relationships of MW181 analogs (Watterson et al.
2013) that MW181 has a naphthyl substituent that occupies
this pocket in p38αMAPK. This substituent contributes to the
drug:target affinity as well as to the selectivity of MW181 for
p38α MAPK vs other proteome targets that lack the three
dimensional features required to engage MW181 in high
affinity binding. Therefore, this drug-resistant mutant mouse
model is an excellent tool to explore directly any potential off-
target effects of MW181 relevant to the pharmacodynamic
effect on proinflammatory cytokine production. In LPS-
stressed p38α KI mice, MW181 was unable to suppress
any of the neuroinflammatory mediators (IL-1β, TNFα,
IL-6, IL-10, or CXCL1), showing levels comparable to
the LPS-stimulated p38α KI mice treated with saline
vehicle (Fig. 2).
Discussion
The studies reported here demonstrate that MW181 en-
gages the p38α MAPK target in its glia cellular context
and links the target engagement to the downstream
pharmacodynamic effect of normalized CNS proinflam-
matory cytokine levels. The in vivo selectivity of MW181
action is further indicated by the failure to bring about its
pharmacodynamic effects in p38α MAPK inhibitor resistant
mice. Taken in its entirety, the results presented here and
previously (Bachstetter et al. 2011; Xing et al. 2013;
Watterson et al. 2013) strongly indicate that the pharmacody-
namic effects of this class of novel, highly selective inhib-
itors of CNS p38α MAPK are via modulation of en-
dogenous p38α MAPK and not other protein kinases, or
serendipitous off-target mechanisms. Our results further
document the utility of MW181 to probe the role of
p38α MAPK in disorders of the CNS that include a
neuroinflammatory component as part of the disease
mechanism.
Acknowledgments We thankDanielle Goulding for excellent technical
assistance. This research was supported in part by funding from the
Alzheimer’s Drug Discovery Foundation (DMW), and NIH grants R01
AG031311 (DMW), U01 AG043415 (DMW), and R01 NS064247
(LVE). ADB was supported in part by NIH/NIA (F32 AG037280 and
K99AG044445).
Competing Interest DMW and LVE are principal investigators on
project funding from the NIH and non-profit disease foundations that
include the study of signal transduction pathways, drug target validation
or development of new molecular entities for treatment of CNS disorders.
Northwestern University has filed patent applications covering commer-
cial use of the novel compounds described herein.
Conflict of Interest The authors declare that they have no conflict of
interest.
Open Access This article is distributed under the terms of the Creative
Commons Attribution License which permits any use, distribution, and
reproduction in any medium, provided the original author(s) and the
source are credited.
J Neuroimmune Pharmacol (2014) 9:454–460 459
References
Arthur JS, Ley SC (2013) Mitogen-activated protein kinases in innate
immunity. Nat Rev Immunol 13:679–692
Bachstetter AD, Van Eldik LJ (2010) The p38 MAP kinase family as
regulators of proinflammatory cytokine production in degenerative
diseases of the CNS. Aging Dis 1:199–211
Bachstetter AD, Xing B, de Almeida L, Dimayuga ER, Watterson DM,
Van Eldik LJ (2011)Microglial p38 alphaMAPK is a key regulator of
proinflammatory cytokine up-regulation induced by toll-like receptor
(TLR) ligands or beta-amyloid (Aβ). J Neuroinflammation 8:12
Bachstetter AD, Rowe RK, Kaneko M, Lifshitz J, Van Eldik LJ (2013)
MAPK p38α regulates microglial responsiveness to diffuse trau-
matic brain injury. J Neurosci 33:6143–6153
Brennan KC, Bates EA, Shapiro RE, Zyuzin J, Hallows WC, Huang Y,
Lee H-Y, Jones CR, Fu Y-H, Charles AC, Ptacek LJ (2013) Casein
kinase 1δ mutations in familial migraine and advanced sleep phase.
Sci Transl Med 5:183ra56, 1–11
Burda JE, Sofroniew MV (2014) Reactive gliosis and the multicellular
response to CNS damage and disease. Neuron 81:229–248
Chico LK, Van Eldik LJ, Watterson DM (2009) Targeting protein kinases
in central nervous system disorders. Nat Rev Drug Discov 8:892–909
Landis SC, Amara SG, Asadullah K, Austin CP, Blumenstein R, Bradley
EW, Crystal RG, Darnell RB, Ferrante RJ, Fillit H, Finkelstein R,
Fisher M, Gendelman HE, Golub RM, Goudreau JL, Gross RA,
Gubitz AK, Hesterlee SE, Howells DW, Huguenard J, Kelner K,
Koroshetz W, Krainc D, Lazic SE, Levine MS, Macleod MR,
McCall JM, Moxley RT III, Narsimhan K, Noble LJ, Perrin S,
Porter JD, Steward O, Unger E, Utz U, Silberberg SD (2012) A call
for transparent reporting to optimize the predictive value of preclin-
ical research. Nature 490:187–191
Morfini GA, Bosco DA, Brown H, Gatto R, Kaminska A, Song Y, Molla
L, Baker L, Marangoni MN, Berth S, Tavassoli E, Bagnato C,
Tiwari A, Hayward LJ, Pigino GF, Watterson DM, Huang CF,
Banker G, Brown RH Jr, Brady ST (2013) Inhibition of fast axonal
transport by pathogenic SOD1 involves activation of p38 MAP
kinase. PLoS One 8:e65235
Mosher KI, Wyss-Coray T (2014) Microglial dysfunction in brain aging
and Alzheimer’s disease. Biochem Pharmacol 88:594–604
O’Keefe SJ, Mudgett JS, Cupo S, Parsons JN, Chartrain NA, Fitzgerald
C, Chen SL, Lowitz K, Rasa C, Visco D, Luell S, Carballo-Jane E,
Owens K, Zaller DM (2007) Chemical genetics define the roles of
p38 alpha and p38 beta in acute and chronic inflammation. J Biol
Chem 282:34663–34671
Pardridge WM (2005) The blood–brain barrier: bottleneck in brain drug
development. NeuroRx 2:3–14
Ransohoff RM (2009) Chemokines and chemokine receptors: standing at
the crossroads of immunobiology and neurobiology. Immunity 31:
711–721
Ransohoff RM, Perry VH (2009) Microglial physiology: unique stimuli,
specialized responses. Annu Rev Immunol 27:119–145
Shanware NP,Williams LM, BowlerMJ, Tibbetts RS (2009) Nonspecific
in vivo inhibition of CK1 by the pyridinyl imidazole p38 inhibitors
SB 203580 and SB 202190. BMB Rep 42:142–147
Shineman DW, Basi GS, Bizon JL, Colton CA, Greenberg BD, Hollister
BA, Lincecum J, Leblanc GG, Lee LH, Luo F, Morgan D, Morse I,
Refolo LM, Riddell DR, Scearce-Levie K, Sweeney P, Yrjanheikki
J, Fillit HM (2011) Accelerating drug discovery for Alzheimer’s
disease: best practices for preclinical animal studies. Alzheimers Res
Ther 3:28
Stewart BH, Chan OH, Lu RH, Reyner EL, Schmid HL, Hamilton HW,
Steinbaugh BA, Taylor MD (1995) Comparison of intestinal per-
meabilities determined in multiple in vitro and in situ models:
relationship to absorption in humans. Pharm Res 12:693–699
Tong L, Prieto GA, Kramar EA, Smith ED, Cribbs DH, Lynch G, Cotman
CW (2012) BDNF-dependent synaptic plasticity is suppressed by
IL-1β via p38 MAPK. J Neurosci 32:17714–17724
Van Eldik LJ, Thompson WL, Ralay Ranaivo H, Behanna HA,
Watterson DM (2007) Glia proinflammatory cytokine upreg-
ulation as a therapeutic target for neurodegenerative diseases:
function-based and target-based discovery approaches. Int Rev
Neurobiol 82:277–296
Verkaar F, van der Doelen A, Smits FM, Blankensteijn M, Zaman G
(2011) Inhibition of Wnt/β-catenin signaling by p38 MAP kinase
inhibitors is explained by cross-reactivity with casein kinase I delta/
epsilon. Chem Biol 18:485–494
Watterson DM, Grum-Tokars VL, Roy SM, Schavocky JP, Bradaric BD,
Bachstetter AD, Xing B, Dimayuga E, Saeed F, Zhang H,
Staniszewski A, Pelletier JC, Minasov G, Anderson WF, Arancio
O, Van Eldik LJ (2013) Development of novel in vivo chemical
probes to address CNS protein kinase involvement in synaptic
dysfunction. PLoS One 8:e66226
Xing B, Bachstetter AD, Van Eldik LJ (2011) Microglia p38αMAPK is
critical for LPS-induced neuron degeneration through a mechanism
involving TNFα. Mol Neurodegener 6:84
Xing B, Bachstetter AD, Van Eldik LJ (2013) Deficiency in p38βMAPK
fails to inhibit cytokine production or protect neurons against
inflammatory insult in in vitro and in vivo mouse models.
PLoS One 8:e56852
460 J Neuroimmune Pharmacol (2014) 9:454–460
